Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor

Summary

Platelet P2Y₁₂ receptors play an important role in arterial thrombosis by stimulating thrombus growth. Both irreversibly (clopidogrel) and reversibly binding (ticagrelor, AZD6140) P2Y₁₂ antagonists are clinically used for restricted periods, but possible differences in platelet function recovery after drug cessation have not been investigated. We treated WKY rats with a single, high dose of 200 mg/kg clopidogrel or 40 mg/ kg ticagrelor. Blood was collected at different time points after treatment. Flow cytometry confirmed full platelet protection against ADP-induced α_IIbβ₃ activation shortly after clopidogrel or ticagrelor treatment. At later time points after clopidogrel treatment, a subpopulation of juvenile platelets appeared that was fully responsive to ADP. Addition of ticagrelor to clopidogrel-treated blood reduced α_IIbβ₃ activation of the unprotected platelets. In contrast, at later time points after ticagrelor treatment, all platelets gradually lost their protection against ADP activation. Perfusion experiments showed abolishment of thrombus formation shortly after clopidogrel or ticagrelor treatment. Thrombus formation on collagen was determined under high shear flow conditions. At later time points, large thrombi formed in the clopidogrel but not in the ticagrelor group, and unprotected, juvenile platelets preferentially incorporated into the formed thrombi. However, platelets from both groups were still similarly reduced in assays of whole blood aggregation. Conclusively, recovery of rat platelet function after ticagrelor differs mechanistically from that after clopidogrel. This difference is masked by conventional platelet aggregation methods, but is revealed by thrombus formation measurement under flow. Juvenile platelets formed at later time points after clopidogrel treatment promoted thrombus formation.

Keywords

Platelet physiology - arterial thrombosis - ADP receptors - pharmacodynamics

• References

• 1 Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
• 2 Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y₁₂ adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174-183.
• 3 Gurbel PA, Tantry US. Drug insight: Clopidogrel non-responsiveness. Nat Clin Pract Cardiovasc Med 2006; 3: 387-395.
• 4 Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
• 5 Fox KA, Mehta SR, Peters R. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110: 1202-1208.
• 6 Kazui M, Nishiya Y, Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
• 7 Bouman HJ, Schomig E, van Werkum JW. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
• 8 Wallentin L, Varenhorst C, James S. et al. Prasugrel achieves greater and faster P2Y₁₂ receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
• 9 Cattaneo M. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-2012.
• 10 Smith SM, Judge HM, Peters G. et al. Common sequence variations in the P2Y₁₂ and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006; 17: 250-258.
• 11 Mylotte D, Peace AJ, Tedesco AT. et al. Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 2011; 9: 24-32.
• 12 Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a „rebound“ phenomenon?. Thromb Haemost 2011; 105: 211-220.
• 13 Van Giezen JJJ, Nilsson L, Berntsson P. et al. Ticagrelor binds to human P2Y₁₂ independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009; 7: 1556-1565.
• 14 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
• 15 Cannon CP, Harrington RA, James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
• 16 Gurbel PA, Bliden KP, Butler K. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
• 17 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
• 18 Van Giezen JJ. Optimizing platelet inhibition. Eur Heart J 2008; 10: D23-29.
• 19 Heemskerk JW, Kuijpers MJ, Munnix IC. et al. Platelet collagen receptors and coagulation. A characteristic platelet response as possible target for antithrombotic treatment. Trends Cardiovasc Med 2005; 15: 86-92.
• 20 Munnix IC, Strehl A, Kuijpers MJ. et al. The glycoprotein VI-phospholipase Cγ2 signaling pathway controls collagen- and tissue factor-induced thrombus formation in vitro and in vivo. Atheroscler Thromb Vasc Biol 2005; 25: 2673-2678.
• 21 Sigfridsson K, Björkman JA, Skantze P. et al. Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound. J Pharm Sci 2011; 100: 2194-2202.
• 22 Van Giezen JJ, Berntsson P, Zachrisson H. et al. Comparison of ticagrelor and thienopyridine P2Y₁₂ binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009; 124: 565-571.
• 23 Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y₁₂ receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-496.
• 24 Bannerman R. The mouse in biomedical research. New York: 1983. Academic Press
• 25 Sibbing D, Braun S, Jawansky S. et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
• 26 Storey RF, May JA, Heptinstall S. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y₁₂ and P2Y₁ antagonists but not aspirin. Thromb Res 2005; 115: 301-307.
• 27 Kuijpers MJ, Gilio K, Reitsma S. et al. Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model. J Thromb Haemost 2009; 7: 152-161.
• 28 Lecut C, Schoolmeester A, Kuijpers MJ. et al. Principal role of glycoprotein VI in α₂β₁ and α_IIbβ₃ activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004; 24: 1727-1733.
• 29 Nergiz-Unal R, Cosemans JM, Feijge MA. et al. Stabilizing role of platelet P2Y₁₂ receptors in shear-dependent thrombus formation on ruptured plaques. Plos One 2010; 5: e10130
• 30 Cosemans JM, van Kruchten R, Olieslagers S. et al. Potentiating role of Gas6 and TAM receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost 2010; 8: 1797-1808.
• 31 Brass L. Fifty (or more) ways to leave your platelets (in a thrombus). Arterioscler Thromb Vasc Biol 2004; 24: 989-991.
• 32 Bal Dit Sollier C, Berge N, Boval B. et al. Functional variability of platelet response to clopidogrel correlates with P2Y₁₂ receptor occupancy. Thromb Haemost 2009; 101: 116-122.
• 33 Patrono C. The P2Y₁₂ receptor: no active metabolite, no party. Nat Rev Cardiol 2009; 6: 271-272.
• 34 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y₁₂ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.